Effects of Liraglutide in Young Adults With Type 2 DIAbetes (LYDIA)

NCT02043054 on ClinicalTrials.gov · last registry update 2020-01-30

A small phase 3 — 90 participants, against a typical 424. The sponsor logged completion for 2 September 2017. Primary outcome, as filed: Change in peak early diastolic strain rate measured by cardiac MRI. liraglutide is already approved in the US for cardiovascular disease and type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.

Status: COMPLETED
Phase: P3
Drug: liraglutide
Saxenda, Victoza, Xultophy
Sponsor: University of Leicester
Sponsor type: Other
Enrollment: 90
Started: 2013-12-16
Primary completion: 2017-09-02 actual

Observed history

No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.

Primary outcome

Change in peak early diastolic strain rate measured by cardiac MRI

Conditions studied

Type 2 Diabetes Mellitus · Cardiovascular Disease

Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.